THE ROLE OF SOME POLYMORPHIC VARIANTS OF 5-ALPHAREDUCTASE GENE IN PATHOGENESIS OF PROSTATE CANCER

In the prostate testosterone, a primary androgen in males, is converted into its most active form, dihydrotestosterone (DHT) by 5α-reductase type 2, encoded by the SRD5A2 gene. Dihydrotestosterone is necessary for prostatic growth and has five times higher binding affinity than testosterone for androgen receptors. We hypothesized that polymorphic variations in the SRD5A2 gene may affect the risk of prostate cancer and analyzed three polymorphisms in the SRD5A2 gene-A49T, V89L and (TA) n in 291 prostate cancer patients and 417 healthy individuals. We found out, that only V89L polymorphism of the SRD5A2 gene contributes to the prostate cancer pathogenesis.

рак предстательной железы, 5-α-редуктаза 2-го типа, дигидротестостерон, ген SRD5A2, prostate cancer, 5-α-reductase 2 type, dihydrotestosterone, SRD5A2 gene

1. Каприн, А.Д. Злокачественные новообразования в России в 2013 году (заболеваемость и смертность) / А.Д. Каприн, В.В. Старинский, Г.В. Петрова. - М.: МНИОИ им. П.А. Герцена филиал ФГБУ «ФМИЦ им. П.А. Герцена» Минздрава России, 2015. - 250 с

2. Parkin, D.M. Cancer burden in the year 2000: the global picture / D.M. Parkin, F.I. Bray, S.S. Devesa // Eur J Cancer. - 2001. -Vol. 37(8). - Р.64-66

3. Раснер, П.И. Гормональная терапия рака предстательной железы. Оценка эффективно-стинеоадъювантной терапии бикалутамидом / П.И. Раснер, Д.Ю. Пушкарь, А.В. Говоров // Современная онкология. - 2008. - № 10(4). - С.55-59

4. Ross, R.K. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility / R.K. Ross, M.C. Pike, G.A. Coet- zee // Cancer Research. - 1998. - Vol. 58. - P. 4497-44504

5. Makridakis, N.M. Association of missence substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA / N.M. Makridakis, R.K. Ross, M.C. Pike // Lancet. - 1999. - Vol. 354. - P. 975-978

6. Makridakis, N.M. Biochemical and pharmacogenetic dissection of human steroid 5a-reductase type II / N.M. Makridakis, E. di Salle, J.K. Reichardt // Pharmacogenetics. - 2000. - Vol. 10. - P. 407-413

7. Edward P.G. Molecular biology of the androgen receptor / P.G. Edward // J Clin Oncol. - 2002. - Vol. 20(13). - P.3001-3015

8. Longer (TA)n Repeat but Not A49T and V89L Polymorphisms in SRD5A2 Gene May Confer Prostate Cancer Risk in South Indian Men / R. Singh [et. al.] // Journal of Andrology. - 2009. - Vol. 30(6). - P.703-710

9. Polymorphisms of HPC2/ELAC2 and SRD5A2 (5α-reductase type II) genes in prostate cancer / M. İzmirli [et al.] // BJMG. - 2011. - Vol. 14(1). - P.31-36

10. Assotiation of polymorphism in testosterone 5-alpha-reductase II genotype and prognosis factors of prostate cancer / M. Tong [et al.] // Zhonghua Yi Xue Za Zhi. - 2005. - V.25-85(19). - P.1319-21

11. Клиническое значение полиморфизмов генов 5α-Редуктазы и андрогенорецепторов при раке предстательной железы / О.Б. Лоран [и др.] // Онкоурология - 2009. - № 1. - С. 48-52

12. Somatic mutations at the SRD5A2 locus encoding prostatic steroid 5a-reductase during prostate cancer progression / A. Akalu [et al.] // J Urol. - 1999. - V.161. - P. 1355-1358

13. Genetic variability of the human SRD5A2 gene: implications for prostate cancer ris / J.K. Reichardt [et al.] // Cancer Res. - 1995. - Vol. 55. - P. 3973- 3975

14. Cancer Incidence in Five Continents / D.M. Parkin [et al.] // Lyon, France, IARC. - 1997. - Vol. 2

15. Type 1 and Type 2 5a-Reductase Expression in the Development and Progression of Prostate Cancer / L.N. Thomas [et al.] // Eur Urol. - 2007. -Vol. 52(4). - P.1082-1087

16. SRD5A2 gene polymorphisms and the risk of benign prostatic hyperplasia but not prostate cancer / V.K. Choubey [et al.] // Asian Pac J Cancer Prev. - 2015. - Vol. 16(3). - P. 1033-1036

17. Steroid 5-alpha-reductase type 2 (SRD5A2) V89L and A49T polymorphisms and sporadic prostate cancer risk: a meta-analysis / Q Li [et al.]// Mol Biol Rep. - 2013. - Vol. 40(5). - P. 3597-3608. doi: 10.1007/s11033-012-2434-x. Epub 2013 Jan 1

18. Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer / X. Li [et al.] // Mutagenesis. - 2011. - Vol. 26(3). - P. 371-83. doi: 10.1093/mutage/geq103